10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||
| ||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBVIE INC. | |||
Ticker: ABBV Fiscal Year: 2022 | |||
Consolidated Statements of Earnings | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
(In Millions) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
Net revenues | $ 58,054 | 56,197 | 45,804 |
Cost of products sold | 17,414 | 17,446 | 15,387 |
Selling, general and administrative | 15,260 | 12,349 | 11,299 |
Research and development | 6,510 | 6,922 | 6,379 |
Acquired IPR&D and milestones | 697 | 1,124 | 1,376 |
Other operating expense, net | 56 | 432 | 0 |
Total operating costs and expenses | 39,937 | 38,273 | 34,441 |
Operating earnings | 18,117 | 17,924 | 11,363 |
Interest expense, net | 2,044 | 2,384 | 2,280 |
Net foreign exchange loss | 148 | 51 | 71 |
Other expense, net | 2,448 | 2,500 | 5,614 |
Earnings before income tax expense | 13,477 | 12,989 | 3,398 |
Income tax expense (benefit) | 1,632 | 1,440 | (1,224) |
Net earnings | 11,845 | 11,549 | 4,622 |
Net earnings attributable to noncontrolling interest | 9 | 7 | 6 |
Net earnings attributable to AbbVie Inc. | 11,836 | 11,542 | 4,616 |
Per share data | |||
Basic earnings per share (in dollars per share) | 6.65 | 6.48 | 2.73 |
Diluted earnings per share (in dollars per share) | 6.63 | 6.45 | 2.72 |
Weighted-average basic shares outstanding (in shares) | 1,771 | 1,770 | 1,667 |
Weighted-average diluted shares outstanding (in shares) | 1,778 | 1,777 | 1,673 |
External Links | |
ABBVIE INC. (ABBV) Fiscal Year 2022 | |
Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |